Currently, there are very few studies investigating the genetic variants of CYP2D6 and CYP2C19 in a population of patients experiencing either ineffectiveness or ADRs to antidepressants in real-world settings, i.e., longitudinally regardless of the indication of treatment (depression, anxiety disorders, and PTSD). Here, CYP2C19 is linked to major depressive disorder.